UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d)
OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of
Report (Date of earliest event reported): November 28, 2005
VioQuest
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
000-16686
|
58-1486040
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
|
|
|
|
7
Deer Park Drive, Suite E
Monmouth
Junction, NJ 08852
(Address
of principal executive offices)
(732)
274-0399
(Registrant's
telephone number, including area code)
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
Written
communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting
material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement
communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement
communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
1.01 Entry
into a Material Definitive Agreement
On
November 29, 2005, the Registrant issued to each of Brian Lenz, the Registrant’s
Chief Financial Officer, Secretary and Treasurer, and Yaping Hong, the
Registrant’s Senior Vice President of Process Research and Development, an
option to purchase 100,000 shares of the Registrant’s common stock at an
exercise price of $1.03 to vest equally over three years on each of November
29,
2006, 2007 and 2008.
Item
5.02 Departure
of Directors or Principal Officers; Election of Directors; Appointment of
Principal Officers.
On
November 28, 2005, David M. Tanen and Kenneth W. Brimmer resigned from the
Registrant’s Board of Directors.
Effective
as of November 29, 2005, the Registrant appointed Johnson Y.N. Lau, M.B.,
B.S.,
M.D., F.R.C.P. to its Board of Directors. Dr. Lau will be appointed to serve
on
the audit and compensation committees of the Board of Directors and will
serve
as the “audit committee financial expert” as such term is defined by SEC
regulations. Dr. Lau qualifies as an “independent director,” as such term is
defined by Section 121(A) of the listing standards of the American Stock
Exchange.
Item
9.01 Financial
Statements and Exhibits.
(c) Exhibits.
99.1 Press
Release dated December 02, 2005.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
|
|
| |
VioQuest
Pharmaceuticals, Inc. |
|
|
|
| Date: December
02, 2005 |
By: |
/s/
Brian Lenz |
| |
Brian
Lenz
Chief
Financial Officer
|
| |
|